Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia
We investigated the efficacy of arsenic trioxide (ATO) in patients with refractory severe aplastic anemia (SAA). A total of 5 consecutive adults were enrolled. The patients received ATO at a dose of 0.15 mg/kg intravenously daily for 5 days every week for 8 weeks. If necessary, a second course was p...
Main Authors: | , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475035/ |